MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

Search

Coherus Oncology Inc

Suletud

SektorTervishoid

1.73 3.59

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.62

Max

1.73

Põhinäitajad

By Trading Economics

Sissetulek

354M

298M

Müük

2.7M

10M

P/E

Sektori keskmine

3.208

37.257

Kasumimarginaal

2,903.911

Töötajad

177

EBITDA

-1.3M

-45M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+141.32% upside

Turustatistika

By TradingEconomics

Turukapital

97M

198M

Eelmine avamishind

-1.86

Eelmine sulgemishind

1.73

Uudiste sentiment

By Acuity

50%

50%

158 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

Coherus Oncology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. okt 2025, 21:50 UTC

Omandamised, ülevõtmised, äriostud

Caterpillar to Acquire Australia's RPM Global for $730 Million

10. okt 2025, 21:38 UTC

Omandamised, ülevõtmised, äriostud

Strathcona Resources Terminates Take-Over Bid for MEG Energy

12. okt 2025, 23:47 UTC

Market Talk

Gold Rises, Buoyed by Monetary Debasement Fears -- Market Talk

12. okt 2025, 23:39 UTC

Market Talk

Oil Rises on Likely Technical Recovery, Mildly Positive Sentiment -- Market Talk

12. okt 2025, 23:22 UTC

Market Talk

New Zealand Braces For Renewed Trade War Uncertainty -- Market Talk

12. okt 2025, 23:16 UTC

Omandamised, ülevõtmised, äriostud

Caterpillar Inc. Enters Into Agreement To Acquire RPMGlobal >CAT RUL.AU

12. okt 2025, 22:32 UTC

Market Talk

Copper, U.S. Thermal Coal Stand Out as Metals Ride Macro Tailwinds -- Market Talk

12. okt 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

RPM Global Says Board Unanimously Recommends Shareholders Accept Caterpillar Offer

12. okt 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

RPM Global Agrees to Takeover by Caterpillar

12. okt 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

RPM Global Says Caterpillar Offering A$5.00/Share in Cash

11. okt 2025, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

11. okt 2025, 00:18 UTC

Omandamised, ülevõtmised, äriostud

Why Biotech May Be Back -- Barrons.com

10. okt 2025, 21:07 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Dell Is Just Beginning to Tell Its AI Story. Buy the Stock. -- Barrons.com

10. okt 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

10. okt 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10. okt 2025, 20:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

10. okt 2025, 20:06 UTC

Market Talk

Fed Won't Publish Monthly Industrial Data Next Week -- Market Talk

10. okt 2025, 20:06 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10. okt 2025, 19:56 UTC

Market Talk

U.S.-China Tension Weighs Down on Treasury Yields, Dollar -- Market Talk

10. okt 2025, 19:20 UTC

Market Talk

Oil Futures Sink As Trump Rekindles Trade Tensions -- Market Talk

10. okt 2025, 19:02 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Loss -- Market Talk

10. okt 2025, 18:58 UTC

Market Talk

Canada's Jobs Gain Marks a 'Head Fake' For Economy -- Market Talk

10. okt 2025, 18:52 UTC

Market Talk

PepsiCo Lays Groundwork for Improvement -- Market Talk

10. okt 2025, 18:47 UTC

Market Talk

Precious Metals Turn Higher After Profit-Taking Slide -- Market Talk

10. okt 2025, 18:35 UTC

Market Talk

Canada's Next Rate Cut May be Pushed to December -- Market Talk

10. okt 2025, 18:31 UTC

Market Talk

Canada's Labor Market Firming. But Conditions Vary Across Country -- Market Talk

10. okt 2025, 17:32 UTC

Market Talk

U.S. Oil Rig Count Declines by Four to 418 -- Market Talk

10. okt 2025, 16:55 UTC

Tulu

These Stocks Are Moving the Most Today: MP Materials, Nvidia, Alibaba, Venture Global, Applied Digital, Qualcomm, and More -- Barrons.com

10. okt 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

10. okt 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Coherus Oncology Inc Prognoos

Hinnasiht

By TipRanks

141.32% tõus

12 kuu keskmine prognoos

Keskmine 4.03 USD  141.32%

Kõrge 7 USD

Madal 1.1 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Coherus Oncology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

3

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

0.9209 / 1.05Toetus ja vastupanu

Lühikene perspektiiv

Weak Bearish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

158 / 371 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
help-icon Live chat